<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34804">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653482</url>
  </required_header>
  <id_info>
    <org_study_id>D1690C00032</org_study_id>
    <nct_id>NCT02653482</nct_id>
  </id_info>
  <brief_title>Dapagliflozin Effect on Symptoms and Biomarkers in Diabetes Patients With Heart Failure</brief_title>
  <acronym>DEFINE-HF</acronym>
  <official_title>Dapagliflozin Effect on Symptoms and Biomarkers in Diabetes Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Luke's Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Luke's Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared
      with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and
      quality of life in patients with type 2 diabetes and chronic heart failure with reduced
      systolic function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of
      once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (BNP and
      NTproBNP), symptoms, health status, and quality of life in patients with type 2 diabetes and
      chronic heart failure with reduced systolic function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the average reduction of NTproBNP between the treatment and placebo study arms from baseline through 12 weeks.</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients that achieve a ≥ 5pts increase in heart failure disease specific quality of life (assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score) or a ≥ 20% decrease in NTproBNP over 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a ≥ 5pts increase in KCCQ</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a ≥ 20% decrease in NTproBNP</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a ≥ 5pts increase in KCCQ and a ≥ 20% decrease in NTproBNP</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in KCCQ score over 12 weeks.</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk score over 12 weeks.</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BNP over 12 weeks.</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c over 12 weeks.</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight over 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure over 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Heart Failure With Reduced Systolic Function</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin 10 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dapagliflozin matching placebo 10 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin matching placebo</intervention_name>
    <arm_group_label>Dapagliflozin matching placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented type 2 diabetes for at least 6 months, treated with at least one
             glucose-lowering medication (oral, non-insulin injectables, or insulin) with a stable
             dose(s) during the 12 weeks prior to enrollment

          2. Hemoglobin A1c of 6.5-11.0% at enrollment

          3. Established diagnosis of NYHA Class II or Class III heart failure (LVEF≤40% due to
             either ischemic or non-ischemic etiology) with reduced systolic function for at least
             16 weeks prior to enrollment

          4. No change in diuretic management for at least 2 weeks prior to enrollment

          5. BNP ≥125 pg/mL and/or NTproBNP ≥ 600 pg/mL at enrollment

        Exclusion Criteria:

          1. History of type 1 diabetes

          2. Estimated glomerular filtration rate (eGFR) &lt; 45 at enrollment

          3. Hospitalization for heart failure within the 60 days prior to enrollment

          4. Admission for an acute coronary syndrome (ST-elevation MI, non-ST-elevation MI, or
             unstable angina), percutaneous coronary intervention, or cardiac surgery within the
             60 days prior to enrollment

          5. Admission for cardiac resynchronization therapy (CRT) within 90 days prior to the
             screening visit

          6. Planned cardiovascular revascularization (percutaneous intervention or surgical) or
             major cardiac surgery (coronary artery bypass grafting, valve replacement,
             ventricular assist device, cardiac transplantation, or any other surgery requiring
             thoracotomy) within the 90 days after enrollment

          7. Patients who are volume depleted based upon physical examination at the time of
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>119 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Kosiborod, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Saint Luke's Mid America Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheryl Windsor</last_name>
    <phone>816-932-9858</phone>
    <email>DEFINE-HF@saint-lukes.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-616-3719</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advocate Health and Hospitals</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-328-7635</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freeman Health System</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>417-347-3493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Truman Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>816-932-5989</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-501-2897</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-970-8924</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-662-4214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0461432268&amp;QV1=DAPAGLIFLOZIN</url>
    <description>Drug information for dapagliflozin</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 1, 2017</lastchanged_date>
  <firstreceived_date>January 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>heart failure</keyword>
  <keyword>dapagliflozin</keyword>
  <keyword>SGLT-2 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
